SNY vs. VRTX, REGN, GSK, BMY, PFE, ZTS, ABT, TAK, NVS, and AZN
Should you be buying Sanofi stock or one of its competitors? The main competitors of Sanofi include Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), GSK (GSK), Bristol-Myers Squibb (BMY), Pfizer (PFE), Zoetis (ZTS), Abbott Laboratories (ABT), Takeda Pharmaceutical (TAK), Novartis (NVS), and AstraZeneca (AZN). These companies are all part of the "pharmaceutical preparations" industry.
Sanofi (NASDAQ:SNY) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.
In the previous week, Sanofi had 2 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 16 mentions for Sanofi and 14 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 1.00 beat Sanofi's score of 0.65 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Sanofi's net margin of 10.52%. Vertex Pharmaceuticals' return on equity of 23.08% beat Sanofi's return on equity.
Sanofi currently has a consensus price target of $55.00, indicating a potential upside of 13.01%. Vertex Pharmaceuticals has a consensus price target of $432.18, indicating a potential downside of 2.93%. Given Sanofi's higher probable upside, equities analysts plainly believe Sanofi is more favorable than Vertex Pharmaceuticals.
10.0% of Sanofi shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 1.0% of Sanofi shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Vertex Pharmaceuticals received 1518 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 75.62% of users gave Vertex Pharmaceuticals an outperform vote while only 53.23% of users gave Sanofi an outperform vote.
Sanofi has higher revenue and earnings than Vertex Pharmaceuticals. Sanofi is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Sanofi has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500.
Summary
Vertex Pharmaceuticals beats Sanofi on 12 of the 18 factors compared between the two stocks.
Get Sanofi News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
